Preliminary results of liver transplantation for hepatocellular carcinoma among allocation organ policy strategies, neoadjuvant treatments, and intention-to-treat analysis

被引:8
作者
Andorno, E. [1 ]
Bottino, G. [1 ]
Morelli, N. [1 ]
Casaccia, M. [1 ]
Gelli, M. [1 ]
Piredda, D. [1 ]
Immordino, G. [1 ]
Ferrante, R. [1 ]
Nardi, I. [1 ]
Troilo, B. M. [1 ]
Di Domenico, S. [1 ]
Ravazzoni, F. [1 ]
Valente, U. [1 ]
机构
[1] San Martino Hosp, Dept Gen Surg & Organ Transplantat, I-16100 Genoa, Italy
关键词
D O I
10.1016/j.transproceed.2008.05.061
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
We retrospectively evaluated the impact of our strategy for patients with hepatocellular carcinoma (HCC) according to an intention-to-treat analysis and drop-out probability. We evaluated only patients within the Milan criteria. We analyzed the outcomes of neoadjuvant strategies for HCC, organ allocation policy, and systematic application of strategies to increase the deceased donor pool as the current tendency to expand transplantability criteria for those patients. Kaplan-Meier survival probability rates at 1, 3, and 5 years according to an intention-to-treat analysis were 87.02%, 74.53%, and 65.93% for transplanted patients (n = 108), and 50%, 14.29%, and 14.29% for the excluded or waiting list group (n = 13), respectively (P < .0001). Drop-out risk at 3, 6, and 12 months was 2.40%, 8.59%, and 16.54%, respectively. During the same period, the mortality probability rates at 3, 6, and 12 months among patients without HCC awaiting orthotopic liver transplantation (OLT) were 3.60%, 9.50%, and 18.34%, respectively. Drop-out rate was lower among patients treated before OLT (P < .0001). On the basis of the neoadjuvant treatment results to reduce drop-out risk, we suggest avoiding the high priority for the HCC cohort, particularly within the first 6 months from entrance on the waiting list, because this approach can reduce the chances of patients with end-stage liver disease (ESLD) alone.
引用
收藏
页码:1972 / 1973
页数:2
相关论文
共 7 条
[1]
Resection prior to liver transplantation for hepatocellular carcinoma [J].
Beighiti, J ;
Cortes, A ;
Abdalla, EK ;
Régimbeau, JM ;
Prakash, K ;
Durand, F ;
Sommacale, D ;
Dondero, F ;
Lesurtel, M ;
Sauvanet, A ;
Farges, O ;
Kianmanesh, R .
ANNALS OF SURGERY, 2003, 238 (06) :885-892
[2]
Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome [J].
Graziadei, IW ;
Sandmueller, H ;
Waldenberger, P ;
Koenigsrainer, A ;
Nachbaur, K ;
Jaschke, W ;
Margreiter, R ;
Vogel, W .
LIVER TRANSPLANTATION, 2003, 9 (06) :557-563
[3]
Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy [J].
Huo, TI ;
Wu, JC ;
Lin, HC ;
Lee, FY ;
Hou, MC ;
Huang, YH ;
Lee, PC ;
Chang, FY ;
Lee, SD .
LIVER TRANSPLANTATION, 2004, 10 (12) :1507-1513
[4]
Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation [J].
Lu, DSK ;
Yu, NC ;
Raman, SS ;
Lassman, C ;
Tong, MJ ;
Britten, C ;
Durazo, F ;
Saab, S ;
Han, S ;
Finn, R ;
Hiatt, JR ;
Busuttil, RW .
HEPATOLOGY, 2005, 41 (05) :1130-1137
[5]
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis [J].
Mazzaferro, V ;
Regalia, E ;
Doci, R ;
Andreola, S ;
Pulvirenti, A ;
Bozzetti, F ;
Montalto, F ;
Ammatuna, M ;
Morabito, A ;
Gennari, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (11) :693-699
[6]
Liver transplantation for hepatocellular cancer: The impact of the MELD allocation policy [J].
Wiesner, RH ;
Freeman, RB ;
Mulligan, DC .
GASTROENTEROLOGY, 2004, 127 (05) :S261-S267
[7]
A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation [J].
Yao, FY ;
Hirose, R ;
LaBerge, JM ;
Davern, TJ ;
Bass, NM ;
Kerlan, RK ;
Merriman, R ;
Feng, S ;
Freise, CE ;
Ascher, NL ;
Robert, JP .
LIVER TRANSPLANTATION, 2005, 11 (12) :1505-1514